Enabling users to embed micro-transponder technology into their hands, BioTeq are aiming to be early movers in the human implantable technology market. The company has featured on BBC, Channel 5 and ITV News and is raising for further research and development.

Investment Terms:
Target: £150,000
Equity: 15.00%
Pre-money valuation: £850,000
Raised: 19%
Investors: 144
Source: Seedinvest
#investment #opportunity #Medical #Implants #Tech #invest #Equity


Maaterra Biotechnologies holds the international patent rights to a product that can easily and cheaply make any washable textile antimicrobial and odour free for a year. The product is already on the market.

Valuation Cap: $8M
Deal Stage: Seed
Minimum Reservation: $25,000
Closing Date: 07/31/2017
Source: Crowdfunder
#investment #opportunity #Laundry #Innovative #Product #invest #Equity


Based on over 30 years of research in the cell electrotaxis field, CELLTech(TM) could be the solution for those who are suffering with motor function loss after an ischemic stroke.

Juno Biomedical was founded on the idea that patient care should heal the underlying cause of disease in a patient-centric manner, rather than merely alleviating the symptoms, Juno Biomedical endeavors to integrate technologies such as digital patient monitoring, bioelectric therapy, and tissue regeneration to create an innovative medical device that can heal brain tissue damage. The company is pioneering advances not only in healing, but in personalized, in-home medical care.
#investment #opportunity #Stroke #Bio #Medical #Treatment #invest #Equity


Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. The company has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.

Lipum also address the treatment of Juvenile Iodiopathic Artrithis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

Lipum´s biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
#investment #opportunity #Chronic #Inflammatory #Disease #Drug #Biotech #growbusinessfinder #invest #Equity #Seeking #Funding


Monocl is a strategy consulting firm specialized on the Life Science industry.
We partner with small and medium sized biotech companies to provide a
competitive edge with lasting business impact.
#investment #opportunity #Biotech #Lifescience #growbusinessfinder #invest #Equity #Seeking #Funding


Since World War II, antibiotics have been the most effective factor in longevity and population expansion. Today, loss of effective antibiotics threatens our medical institutions – antibiotic resistance is a serious problem already or will be within the decade. QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.
Source: #NordicTech
#investmentopportunity #privateequity a #invest #biotech #growbusinessfinder

The future drug delivery system

InoLife is a drug delivery company committed to commercializing innovative product for the care and cure of our global clients

InoLife Technologies Inc. is a publicly traded company, trading on the OTC Markets QB under the trading symbol INOL. The company has acquired the intellectual properties to a needle free injection system.

For investment interest, please contact:

BioTech Startup Opportunity

NovaHep, Gothenburg, Sweden, is a biotechnology company founded as a spin-off from the Karolinska Institute with a unique, proprietary technology in the field of regenerative medicine.

NovaHep is addressing a great, unmet medical need by focusing on tissues that are not easily replaced by synthetic or semi-synthetic prosthetic grafts.

To find out more about this opportunity, contact us on: